Lori Anderson is the Senior Product Manager for VisualStrata at XIFIN, where she brings many years of experience in medical affairs and product portfolio management in the healthcare and life-sciences industries. Prior to joining XIFIN, Lori was the director of health economics and outcomes research at Quest Diagnostics where she defined the reimbursement strategy for numerous tests routinely used in precision medicine. As a laboratorian herself with a particular interest in hematological neoplasms and the role of platelets in cardiovascular disease, Lori has contributed to the publication of 10 book chapters, 20 peer reviewed publications and over 40 poster presentations and has presented on numerous topics in laboratory medicine and life sciences worldwide.
Feyi Ayodele is the co-founder and CEO of CancerIQ, a fast-growing precision health platform that allows providers to identify, evaluate and manage entire patient populations based on individual genetic risk factors. In 2013, Ayodele co-founded CancerIQ after taking a sabbatical from the finance world to work alongside her mother, renowned medical oncologist Olufunmilayo Olopade, in the Center for Clinical Cancer Genetics at University of Chicago.
CancerIQ’s mission is to make sure more people have access to the right genetic testing services and the right preventive care so cancer can be caught early or the risk can be eliminated altogether.
Ayodele’s CancerIQ’s precision health platform has been rapidly adopted by more than 65 health systems and hundreds of providers across the United States, helping to inform care for hundreds of thousands of patients.
Embracing the shift to connected care, CancerIQ fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, improve patient outcomes and savings.
In response to the COVID-19 pandemic, Ayodele led CancerIQ telehealth efforts so providers could identify high-risk patients with potential cancer diagnoses, replace lost in-person visit volume, and triage care to avoid a second wave of COVID-19 related deaths.
In recognition of her success, Ayodele was named to Crain’s Chicago Business 40 under 40 list in 2019 and has won multiple honors including the Chicago Booth New Venture Challenge, a fellowship from Rock health, and 1776’s Global Challenge Cup.
Jonathan Baden is a Senior Director, Pharmacodiagnostics in the Bristol-Myers Squibb Translational Medicine organization. He joined BMS in September 2017 and supports evaluation, strategy, development and execution of the companion/complementary biomarker diagnostic programs for BMS that enhance value of the pharmaceutical product profiles. Jon leads a PDx matrix subteams to execute upon solid tumor and liquid biopsy NGS related strategies pertaining to patient selection (genomic signatures) and disease monitoring (ctDNA). He provides strategic direction to business development led searches, evaluations and transactions for diagnostic partnering. In addition, Jon coordinates activities between the Development, Commercial teams and external diagnostic partners and is responsible for delivery of diagnostic partner critical milestones. Prior to joining BMS, Jon led diagnostic strategies aligned with therapeutic disease areas for the development of stand-alone and companion diagnostic at Janssen Pharmaceuticals and J&J subsidiaries. Jon led matrix teams both internally and with external partners for the management, execution and resolution of assay process for all stages of the product development life cycle. Jon has expertise in oncology disease states (prostate, bladder, lung, breast, and colorectal cancers), autoimmune diseases (Crohn’s and lupus) and infectious diseases (HIV, HCV, IFV, RSV, Ebola) and managed an exploratory NGS team and a late stage development team accountability for products on a fully integrated MDx platform.
Holly has over 20 years of leadership experience in the clinical lab and diagnostics arena, including 15 years of product commercialization, reimbursement, and sales leadership. As VP of Commercial Development, North America for Microba, an early stage microbial genomics company, she is responsible for commercialization, product and channel development, and reimbursement strategy. Previous positions include SVP of Commercial Operations for Lineagen, a pediatric, neurodevelopment genetic testing company, where she built the commercial infrastructure including Market Access, Sales, Marketing, and Reimbursement and lead the organization to triple digit volume growth and substantial payer coverage. Holly also spent over 7 years at PerkinElmer, a global life sciences company. There in her role as National Director of Lab Services Sales and Managed Markets, she led the commercial launch of several key prenatal tests including a proprietary first trimester biochemical screen for birth anomalies, Non-invasive prenatal testing, and carrier screening. She established significant reimbursement profiles for the PerkinElmer clinical test portfolio. She was also instrumental in the commercial development of new tests for preeclampsia and preterm birth.
Holly has a BS in Health Science from East Stroudsburg University.
Patricia Goede is VP Clinical Informatics at XIFIN, Inc., where she brings 22 years’ experience developing biomedical imaging informatics solutions and technology to facilitate multi-modality and multispecialty image-based exchange, collaboration, and management in distributed environments. Goede founded VisualShare and served as CEO until its acquisition by XIFIN in 2015. Previously, Goede was at the University of Utah where she pioneered a number of image, visualization and collaboration tools. She is the founder of the Electronic Medical Education Resource Group (EMERG), and as its director, established the Utah Center of Excellence for Electronic Medical Education. Goede holds an MS in Computational Visualization and a PhD. in Biomedical Imaging Informatics.
Martyn Gross is Chief Business Officer at Mindera. Previously, Mr. Gross was President of Stratify Genomics which commercialized a genetic test for lifetime predisposition to prostate cancer. There, he brought the company from a successful IP license to revenue and important commercial partnerships. Mr. Gross previously served as the COO of Dthera Sciences, a neurodegenerative disease therapy company that was given the first FDA Breakthrough Device status for a digital therapeutic. His prior role was as the founder of Clarify Medical, a novel connected home phototherapy device used by chronic skin disease patients. Mr. Gross serves as a strategic advisor to other personalized medical startups in the San Diego area. He holds an MBA from Rady School of Management, UC San Diego.
Mark Hiatt, currently Vice President for a precision oncology company, has served as the chief medical executive for a multi-state Blues plan and a national medical benefits manager, and departmental leader and board member for a regional health system. Dr. Hiatt completed a fellowship in cardiovascular imaging at Stanford University, residency in radiology and master’s in Health Evaluation Sciences at the University of Virginia, and MD and MBA with academic distinction at Wake Forest University. He is the recent chair of the Greater Salt Lake Chapter of the American Red Cross.
Senior Research Analyst, Medical Policy & Technology Evaluation, Independence Blue Cross
As a Senior Research Analyst for Medical Policy and Technology Evaluation for Independence Blue Cross, Eugean Jiwanmall has served as subject-matter expert, writer, reviewer, communicator, presenter, consultant, adviser, facilitator, and decision maker for hundreds of medical policy topics and technology assessments spanning dozens of clinical disciplines and multiple business areas.
Eugean holds a bachelor’s in biological sciences with honors from Drexel University, master’s of public health in evaluative clinical sciences from Dartmouth Medical School, and MBA in healthcare management and economics with honors from Drexel University, and is completing graduate studies in bioethics at the University of Pennsylvania School of Medicine.
Chief Executive Officer and Founder, Ischemia Care
Jeff June’s background is working with great teams as a startup founder, investor, and educator in innovation across industries based on application of breakthrough technologies. IPO experience. Broad investing experience with a large private equity group and a seed fund in the Midwest. Endowed professor and chair at a major university creating programs in entrepreneurship, engineering and digital. Currently Founder, CEO, investor, and Board Member at Ischemia Care, a company transforming stroke care with the world’s first blood testing for ischemic stroke.
In addition to being the host of the award-winning Precision Medicine Podcast, Jerome Madison leads provider relations and lab integration at Trapelo Health. Jerome is a 14-year veteran of the precision cancer movement who has led the most successful companies in the genomic testing space to become market leaders. He helped create best practices for market access and adoption of clinical genomics and bring his vast network and knowledge to Intervention Insights to develop the network of providers to launch Trapelo. In addition to leading start-ups and building people in the industry, Jerome is also a certified executive coach, a published author and keynote speaker on the topic of innovation.
Hannah Mamuszka is the Founder and CEO of Alva10, which focuses on bringing diagnostics to the forefront of Precision Medicine by partnering with payers and employers with diagnostic developers to create a new value-based healthcare model that pulls diagnostics into the market. Ms Mamuszka has spent more than 20 years in biotech and diagnostics, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She is a Board Director at Bionano Genomics (BNGO), regularly speaks on issues regarding advancement of technology in healthcare, and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Chief Executive Officer, Concert Genetics; Adjunct Professor, Vanderbilt University
Rob currently serves as the Chief Executive Officer of Concert Genetics, a leading provider of data and digital infrastructure for genetic testing and precision medicine. Since joining Concert Genetics in 2016, Rob has spearheaded the company’s strategy to bring transparency, connectivity and efficiency to molecular diagnostics and personalized medicine. Rob co-founded the Genetic Health Information Network Summit, and remains a vocal advocate for spurring innovation and reducing costs in health care.
Prior to joining Concert Genetics, Rob served as President & Chief Operating Officer for Digital Reasoning. Under Rob’s leadership, Digital Reasoning grew to a global leader in cognitive computing software. Rob architected the company’s strategy of leveraging a proprietary, machine-learning platform to automate high-cost, high-value activities such as electronic communication surveillance (financial services), investigations (national security and law enforcement), and adverse event detection (healthcare). Rob led Digital Reasoning’s strategic partnerships, highlighted by investments from In-Q-Tel, Goldman Sachs, and Hospital Corporation of America.
Prior to joining Digital Reasoning, Rob built software and information services businesses for LexisNexis in Mexico City, Toronto, and Raleigh. Rob also worked as a strategy consultant with the Parthenon Group in Boston and San Francisco.
Rob is an Adjunct Professor at Vanderbilt University’s Owen School of Management, as well as frequent speaker on precision medicine, healthcare economics, and artificial intelligence. Rob lives in Nashville with his wife and four children.
Dr. Bruce Quinn is an expert on health reform, innovation, and Medicare policy. A pathologist by training, he has worked on a wide range of federal health policy issues ranging from biopharma to genomics. After a career in academic medicine, he was a physician executive with Accenture, serving clients in both the biopharma and payer industries. After a stint as policymaker with Medicare, he served as a full-time life sciences strategy consultant, serving clients of two major law firms, Foley Hoag LLP and Faegre Baker Daniels LLP. Since 2017, Dr. Quinn manages his own medtech and biotech consulting practice based in Los Angeles and San Francisco. His blog, Discoveries in Health Policy, current logs over 100,000 hits per year. Dr. Quinn has helped leading companies in both the medical device and genomics industries negotiate with CMS agency on coding, coverage, and policy issues.
Satabhisa Mukhopadhyay, PhD, is Founder and Chief Scientist at 4DPath Inc, where she brings her years of innovative cross-disciplinary research and leadership to build a novel scientific approach to revolutionize the crosstalk between pathology and oncology, empowering personalized therapy. Satabhisa is a physicist by training, receiving her PhD in Theoretical Physics from Rutgers University and MS in applied Mathematics from the University of Cambridge. She has years of research experience in biomedical science, cancer cell biology and pharmacology at MIT and Harvard Medical School. Her research interest always evolved around developing machine learning and statistical physics-based models to build methodologies that directly address real life translational questions, especially on cancer drug resistance, at systems level. Satabhisa also has research and leadership experience in algorithmic trading at hedge funds from algorithm development to trading system deployment.
Nancy Zhang, Associate Director, Pharmacodiagnostics in the Bristol-Myers Squibb Translational Medicine organization. Nancy joined BMS in September 2018, provides subject matter expertise related to development and execution of the companion/complementary biomarker diagnostic programs for BMS product development and brand teams. She leads matrix teams of gene expression profiling and ctDNA for MRD and disease monitoring in solid tumor. Prior to joining BMS, Nancy was a companion/complimentary diagnostic lead at Amgen Translational Medicine organization. Prior to Amgen Nancy was the development team lead at Agilent Companion Diagnostic, where she led a team developed the PD-L1 22C3 pharmaDx.